We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. As Healio previously reported, more than 90% of ...
Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...
WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic ...
Learn everything you need to know about Octreotide-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. Diarrhea is one of the dose-limiting toxicities for administration of ...
Seufert et al. (Dec. 27 issue) 1 describe a man with tumor-induced (oncogenic) osteomalacia, in which the subcutaneous administration of octreotide abolished renal tubular phosphate wasting. The ...
- Patients on pasireotide (SOM230) LAR were 63% more likely to achieve full biochemical control than those on Sandostatin LAR, the current standard of care[1] - Acromegaly, a rare endocrine disorder ...
Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov ...
EAST HANOVER, N.J., May 5, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor ® LAR (pasireotide LAR; SOM230) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback